Abstract
While ovarian cancer (OvCa) responds well to surgery and conventional chemotherapy, a high recurrence rate of advanced OvCa is observed. In this phase I/II study, 10 OvCa patients with minimal residual disease were treated with autologous dendritic cells (DCs) and IL-2 to evaluate the safety and feasibility of this therapeutic strategy and to characterize the antigen-specific immune alterations induced through this treatment. Approximately 4 months after initial debulking and chemotherapy, patients received two subcutaneous doses of autologous monocyte-derived DCs pulsed with autologous tumor lysate and keyhole limpet hemocyanin (KLH) at 4-week intervals. After each DC inoculation, low-dose (200 mIU) IL-2 was introduced for 14 consecutive days as an immune adjuvant. The vaccination was well tolerated. In three out of 10 patients, the inclusion status after the initial therapy showed the maintenance of complete remission (CR) after DC vaccination for 83, 80.9 and 38.2 months without disease relapse. One patient with stable disease (SD) experienced the complete disappearance of tumor after DC vaccination, and this status was maintained for 50.8 months until tumor recurrence. In two patients with partial response (PR) was not responding to DC vaccination and their disease recurred. In the three patients with disease free long-term survival, significant immune alterations were observed, including increased natural killer (NK) activity, IFN-γ-secreting T cells, immune-stimulatory cytokine secretion and reduced immune-suppressive factor secretion after DC vaccination. Thus, in patients with NED status and increased overall survival, DC vaccination induced tumor-related immunity, potentially associated with long-term clinical responses against OvCa.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5: 19–24.
Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8–31.
Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112–1115, 2001. Clin Cancer Res 2001; 7: 1154–1162.
Cannon MJ, Santin AD, O'Brien TJ . Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004; 16: 87–92.
Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK . Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 2004; 199: 1503–1511.
Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007; 125: 257–267.
Baek S, Kim CS, Kim SB, Kim YM, Kwone SW, Kim Y et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med 2011; 9: 178.
Ragde H, Cavanagh WA, Tjoa BA . Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2004; 172: 2532–2538.
Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003; 52: 155–161.
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012; 61: 629–641.
Kandalaft LE, Powell Jr DJ, Chiang CL, Tanyi J, Kim S, Bosch M et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2: e22664.
Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61: 373–384.
Bernal SD, Ona ET, Riego-Javier A, R DEV, Cristal-Luna GR, Laguatan JB et al. Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells. Oncol Lett 2012; 3: 66–74.
Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412–1414.
Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J et al. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005; 175: 5058–5066.
Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK . Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 2005; 202: 1375–1386.
Lissoni P . Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J Sci Am 1997; 3( Suppl 1): S115–S120.
Steinman RM, Banchereau J . Taking dendritic cells into medicine. Nature 2007; 449: 419–426.
Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM . Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1–14.
Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K . Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol 1983; 130: 988–992.
Antony GK, Dudek AZ . Interleukin 2 in cancer therapy. Curr Med Chem 2010; 17: 3297–3302.
Antony PA, Restifo NP . CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005; 28: 120–128.
Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169–1177.
Ahmadzadeh M, Rosenberg S A. IL-2 administration increases CD4+ CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107: 2409–2414.
deLeeuw RJ, Kost SE, Kakal JA, Nelson BH . The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18: 3022–3029.
Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86: 1455–1462.
Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004; 37: 363–369.
Acknowledgements
This study was supported through grants from the Korean Ministry of Knowledge Economy (#10021360) and the Samsung Biomedical Research Institute (#SBRI C-A8-501-2).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare that there are no competing interests.
Dr Hyunsoo Kim and Dr Yongman Kim from FCB Pharmicell Co. provided the clinical-grade therapeutic DCs prepared at the KGMP facility. Clinical-grade therapeutic DCs were provided with no commercial relevance associated with FCB Pharmicell.
Rights and permissions
About this article
Cite this article
Baek, S., Kim, YM., Kim, SB. et al. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol 12, 87–95 (2015). https://doi.org/10.1038/cmi.2014.40
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2014.40
Keywords
This article is cited by
-
Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666
British Journal of Cancer (2023)
-
CD8α+ dendritic cells potentiate antitumor and immune activities against murine ovarian cancers
Scientific Reports (2023)
-
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Journal of Hematology & Oncology (2022)
-
Antitumour dendritic cell vaccination in a priming and boosting approach
Nature Reviews Drug Discovery (2020)
-
Thermal stability and secondary structure of feruloylated Rapana thomasiana hemocyanin
Journal of Thermal Analysis and Calorimetry (2019)